IndraLab

Statements


4 | 1 17

eidos
"Bortezomib prevents protein degradation , including RelA via the intracellular NF-kB pathway ."

reach
"Bortezomib treatment in steatotic liver donor reduces NF-kappaB p65 activation and inflammatory I/R injury, improving transplant outcomes of steatotic grafts in a rat model [XREF_BIBR]."

reach
"Furthermore, inhibition of pan-caspases abolished Bortezomib induced degradation of p65, p105 and Sp proteins, but not that of IkappaBalpha."
| PMC

reach
"Moreover, we found that Bortezomib degraded p65 in leukemia cells."
| PMC

No evidence text available

reach
"As shown in XREF_FIG, bortezomib reduces the level of nuclear p65 protein in U266 myeloma cells."

reach
"Bortezomib degraded both cytoplasmic and nuclear pools of p65."
| PMC

reach
"Why Bortezomib degrades p65 is not clear."
| PMC

reach
"The cytoplasmic to nuclear translocation and activation of NF-kappaB is a proteosome-dependant process, and bortezomib has been shown to inhibit nuclear activation of the RelA and NF-kappaB1 subunits in HNSCC [XREF_BIBR]."

reach
"Bortezomib also induced degradation of p65 in a dose dependent manner (XREF_FIG), starting at 10-15 nM, and a time dependent manner, starting after 12 h (XREF_FIG)."
| PMC

reach
"In our study, Bortezomib degraded not only IkappaBalpha protein but also the p65 subunit of NF-kappaB."
| PMC

No evidence text available

No evidence text available

reach
"Similarly, siRNA experiments that inhibit p65 expression and mimic Bortezomib induced degradation of p65 proteins, confirmed that absence or inhibition of p65 does not lead to apoptosis, as represented by the absence of PARP cleavage (XREF_FIG, left panel), nor to induced cell death (XREF_FIG, right panel)."
| PMC

reach
"They showed that proteasome inhibitor bortezomib more effectively inhibited nuclear localization of RELA and p50 than cREL or alternate pathway subunits NF-kappaB2 or RELB in tumor specimens and lines from patients with HNSCC."

reach
"Western blotting showed that Bortezomib induced degradation of Sp3 and p65 in both cytoplasm and nucleus."
| PMC

reach
"While bortezomib inhibited proteasome, NF-kappaB p65 subunit, and prosurvival genes, 18 clinical activity of bortezomib plus reirradiation was limited."

No evidence text available

reach
"In contrast, p65 mRNA expression was unaffected or even increased in MOLT4 cells, implying that bortezomib perturbs the stability of p65 via NICD downregulation as suggested previously."

reach
"Bortezomib indeed decreases nuclear retention of p65 preferentially in PARP inhibitor resistant lines compared to parental UWB1.289 or HCC1937 cells, suggesting that it seems to inhibit NF-kappaB signaling in the setting of acquired PARP resistance."

reach
"We found that Bortezomib degrades p65 and IkappaBalpha through different mechanisms."
| PMC

reach
"After 3 or 7 days of treatment, Disease Activity Index (DAI) as well as histological scores and NF-kappaB p65 protein expression were significantly reduced in mice treated with bortezomib at a dose of 0.6 or 1 mg/kg/day."